A clinical trial explores whether tailoring gout treatment to the underlying cause of elevated uric acid can improve outcomes. Credit: Stock Should doctors rethink the standard gout treatment? Gout ...

Innorna, a clinical‑stage biotech company advancing RNA medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IN026 ...

STOCKHOLM, Feb. 9, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) Sobi® (STO: SOBI) and Arthrosi Therapeutics, Inc. (Arthrosi) announced today the completion of the acquisition of Arthrosi by ...

Racial disparities in gout and gout treatment are an ongoing but tractable problem, research at the 2025 American College of Rheumatology (ACR)'s annual meeting suggested. In a 10-year ...

- Acquisition expected to be highly accretive to Sobi's mid- to long-term growth and margin trajectory "The acquisition of Arthrosi allows us to expand our gout pipeline with a highly differentiated ...

A majority of patients receiving 5 years of treat-to-target urate-lowering therapy maintained target serum uric acid levels and continued to show decreases in signs of crystal deposits and tophi. Only ...

Prolonged hyperuricemia is a major risk factor for gout, which is now regarded as a curable disease. Awareness of the various factors that can trigger gout flares is essential for their prevention. An ...

Over the years, gout has grown in clinical complexity. We see many more cases with iatrogenic factors, multiple comorbidities, advanced age and treatment-refractory hyperuricemia and arthritis (Table ...

Enrollment complete in the replicate REDUCE 1 and REDUCE 2 Phase 3 studies with pivotal data expected in Q2 2026 SAN DIEGO, Oct. 8, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage ...